104 related articles for article (PubMed ID: 30826661)
1. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; ; ; ;
Eur J Cancer; 2019 Apr; 111():94-106. PubMed ID: 30826661
[TBL] [Abstract][Full Text] [Related]
2. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.
Thol F; Gairing SJ; Czauderna C; Thomaidis T; Gamstätter T; Huber Y; Vollmar J; Lorenz J; Michel M; Bartsch F; Müller L; Kloeckner R; Galle PR; Wörns MA; Marquardt JU; Moehler M; Weinmann A; Foerster F
JHEP Rep; 2022 Mar; 4(3):100417. PubMed ID: 35141511
[TBL] [Abstract][Full Text] [Related]
5. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy.
Hsu CC; Liu KH; Chang PH; Chen PT; Hung CY; Hsueh SW; Yeh KY; Chen YY; Lu CH; Hung YS; Chou WC
J Gastroenterol Hepatol; 2020 Oct; 35(10):1694-1703. PubMed ID: 31711261
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
Adhikaree J; Madhusudan S
Med Oncol; 2014 Jul; 31(7):46. PubMed ID: 24913810
[TBL] [Abstract][Full Text] [Related]
8. [Prediction model for survival in patients with biliary tract cancer: a development and validation study].
Han L; Cui P; Tang MS; Zhang M; Cui HJ; Zeng ZQ; Chen SY; Liu SS; Song B; Gu DQ; Wang X; Zhang B
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1461-1469. PubMed ID: 31838822
[No Abstract] [Full Text] [Related]
9. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
11. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
12. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
[TBL] [Abstract][Full Text] [Related]
13. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
14. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L; Cereda S; Aprile G; Di Girolamo S; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Vivaldi C; Belli C; Bergamo F; Lutrino SE; Filippi R; Russano M; Vaccaro V; Brunetti AE; Rotella V; Falcone A; Barbera MA; Corbelli J; Fasola G; Aglietta M; Zagonel V; Reni M; Vasile E; Brandi G
Br J Cancer; 2014 Apr; 110(9):2165-9. PubMed ID: 24714745
[TBL] [Abstract][Full Text] [Related]
15. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
[TBL] [Abstract][Full Text] [Related]
16. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Moik F; Riedl JM; Winder T; Terbuch A; Rossmann CH; Szkandera J; Bauernhofer T; Kasparek AK; Schaberl-Moser R; Reicher A; Prinz F; Pichler M; Stöger H; Stotz M; Gerger A; Posch F
Sci Rep; 2019 Apr; 9(1):5548. PubMed ID: 30944390
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Saisho T; Okusaka T; Ueno H; Morizane C; Okada S
Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750
[TBL] [Abstract][Full Text] [Related]
18. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.
Li H; Zhao T; Ji X; Liang S; Wang Z; Yang Y; Yin J; Wang R
Tumour Biol; 2016 Mar; 37(3):3535-42. PubMed ID: 26453118
[TBL] [Abstract][Full Text] [Related]
19. Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.
Moriwaki T; Ishige K; Araki M; Yoshida S; Nishi M; Sato M; Yamada T; Yamamoto Y; Ozeki M; Ishida H; Yamaguchi T; Matsuda K; Murashita T; Abei M; Hyodo I
Med Oncol; 2014 Nov; 31(11):287. PubMed ID: 25316268
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
